[go: up one dir, main page]

BG101687A - Заместени азетидин-2-они за лечение на атеросклероза - Google Patents

Заместени азетидин-2-они за лечение на атеросклероза

Info

Publication number
BG101687A
BG101687A BG101687A BG10168797A BG101687A BG 101687 A BG101687 A BG 101687A BG 101687 A BG101687 A BG 101687A BG 10168797 A BG10168797 A BG 10168797A BG 101687 A BG101687 A BG 101687A
Authority
BG
Bulgaria
Prior art keywords
atherosclerosis
ones
treatment
substituted azetidin
azetidin
Prior art date
Application number
BG101687A
Other languages
Bulgarian (bg)
English (en)
Inventor
Deirdre HICKEY
Colin LEACH
Robert IFE
David TEW
Dashyant Dhanak
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9426020.5A external-priority patent/GB9426020D0/en
Priority claimed from GBGB9426030.4A external-priority patent/GB9426030D0/en
Priority claimed from GBGB9511599.4A external-priority patent/GB9511599D0/en
Priority claimed from GBGB9511600.0A external-priority patent/GB9511600D0/en
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of BG101687A publication Critical patent/BG101687A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG101687A 1994-12-22 1997-06-26 Заместени азетидин-2-они за лечение на атеросклероза BG101687A (bg)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9426020.5A GB9426020D0 (en) 1994-12-22 1994-12-22 Novel compounds
GBGB9426030.4A GB9426030D0 (en) 1994-12-23 1994-12-23 Novel compounds
GBGB9511599.4A GB9511599D0 (en) 1995-06-08 1995-06-08 Novel compounds
GBGB9511600.0A GB9511600D0 (en) 1995-06-08 1995-06-08 Novel compounds
PCT/EP1995/005130 WO1996019451A1 (fr) 1994-12-22 1995-12-20 Azetidin-2-ones substituees, destinees au traitement de l'atherosclerose

Publications (1)

Publication Number Publication Date
BG101687A true BG101687A (bg) 1998-02-27

Family

ID=27451242

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101687A BG101687A (bg) 1994-12-22 1997-06-26 Заместени азетидин-2-они за лечение на атеросклероза

Country Status (24)

Country Link
US (1) US5990102A (fr)
EP (1) EP0799200A1 (fr)
JP (1) JPH11500415A (fr)
CN (1) CN1175246A (fr)
AP (1) AP9701007A0 (fr)
AR (1) AR002012A1 (fr)
AU (1) AU704407B2 (fr)
BG (1) BG101687A (fr)
BR (1) BR9510420A (fr)
CA (1) CA2208530A1 (fr)
CZ (1) CZ192297A3 (fr)
DZ (1) DZ1958A1 (fr)
FI (1) FI972584L (fr)
HU (1) HUT77089A (fr)
IL (1) IL116485A0 (fr)
MA (1) MA23834A1 (fr)
MX (1) MX9704736A (fr)
NO (1) NO972909L (fr)
NZ (1) NZ298416A (fr)
OA (1) OA10737A (fr)
PL (1) PL320937A1 (fr)
SK (1) SK80397A3 (fr)
TR (1) TR199501655A2 (fr)
WO (1) WO1996019451A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9609445A (pt) * 1995-07-01 1999-04-06 Smithkline Beecham Plc Derivados de azetidinona no tratamento de aterosclerose
WO1997021676A1 (fr) * 1995-12-08 1997-06-19 Smithkline Beecham Plc Composes azetidinone destines au traitement de l'atherosclerose
WO1997021675A1 (fr) * 1995-12-08 1997-06-19 Smithkline Beecham Plc Derives de beta-lactame monocycliques utilises dans le traitement de l'atherosclerose
AU2698697A (en) * 1996-04-26 1997-11-19 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis
GB9608649D0 (en) * 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
AU4654199A (en) * 1998-07-23 2000-02-14 Shionogi & Co., Ltd. Monocyclic beta-lactam compounds and chymase inhibitors containing the same
PT1686119E (pt) 2000-02-16 2009-10-06 Smithkline Beecham Plc Derivados de pirimidin-4-ona como inibidores de ldl-pla2
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
ME00145B (me) 2001-01-26 2010-10-10 Merck Sharp & Dohme Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije
ES2272776T3 (es) 2001-09-21 2007-05-01 Schering Corporation Tratamiento de xantomas con derivados de azetidinona como inhibidores de la absorcion de esterol.
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
WO2004043457A1 (fr) 2002-11-06 2004-05-27 Schering Corporation Inhibiteurs d'absorption de cholesterol pour le traitement de troubles auto-immuns
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7192944B2 (en) * 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2005107767A2 (fr) * 2004-05-03 2005-11-17 Ilypsa, Inc. Modulation de la lysophosphatidylcholine et traitement des etats induits par un regime alimentaire
MX2009012197A (es) 2007-05-11 2010-01-15 Univ Pennsylvania Metodos para tratamiento de ulceras en la piel.
MX2009012188A (es) 2007-05-11 2010-02-24 Univ Jefferson Métodos de tratamiento y prevención de enfermedades y desórdenes neurodegenerativos.
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
UY33766A (es) 2010-12-06 2012-06-29 Glaxo Group Ltd COMPUESTOS CON ESTRUCTURA DE PIRIMIDINONA PARA USO EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR Lp-PLA2
EP2651403B1 (fr) 2010-12-17 2020-12-02 Glaxo Group Limited Procédés de traitement et de prévention de maladies oculaires
US20140171431A1 (en) 2011-06-27 2014-06-19 Jianhua Shen Azole heterocyclic compound, preparation method, pharmaceutical composition and use
EP2739627A4 (fr) 2011-07-27 2015-01-21 Glaxo Group Ltd Composés 2,3-dihydroimidazo[1,2-c]pyrimidin-5(1h)-one et utilisation en tant qu'inhibiteurs de lp-pla2
UY34216A (es) 2011-07-27 2013-02-28 Glaxo Group Ltd Nuevos compuestos que inhiben la actividad de la Lp-PLA2
AU2014210260B2 (en) 2013-01-25 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Bicyclic pyrimidone compounds as inhibitors of Lp-PLA2
KR20150108897A (ko) 2013-01-25 2015-09-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 2,3-디히드로이미다졸[1,2-c]피리미딘-5(1h)-온계의 지단백질-연관 포스포리파제 a2 (lp-pla2) 억제제
WO2014114248A1 (fr) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Composés
WO2015179293A1 (fr) * 2014-05-18 2015-11-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activateurs et inhibiteurs de petites molécules de lécithine-cholestérol acyltransférase
WO2016012917A1 (fr) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
WO2016012916A1 (fr) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
EP4056571A4 (fr) 2019-11-09 2024-01-24 Shanghai Simr Biotechnology Co., Ltd. Dérivé de dihydroimidazopyrimidone tricyclique, son procédé de préparation, composition pharmaceutique et son utilisation
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5559193A (en) * 1978-09-20 1980-05-02 Glaxo Group Ltd Bblactam compound
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
SK80397A3 (en) 1998-01-14
WO1996019451A1 (fr) 1996-06-27
NO972909D0 (no) 1997-06-20
NZ298416A (en) 1999-03-29
JPH11500415A (ja) 1999-01-12
AP9701007A0 (en) 1997-07-31
AR002012A1 (es) 1998-01-07
EP0799200A1 (fr) 1997-10-08
CZ192297A3 (en) 1997-11-12
CA2208530A1 (fr) 1996-06-27
FI972584A0 (fi) 1997-06-17
CN1175246A (zh) 1998-03-04
MA23834A1 (fr) 1996-10-01
MX9704736A (es) 1997-10-31
IL116485A0 (en) 1996-08-04
AU4389896A (en) 1996-07-10
TR199501655A2 (tr) 1996-07-21
NO972909L (no) 1997-08-20
FI972584A7 (fi) 1997-08-19
FI972584L (fi) 1997-08-19
DZ1958A1 (fr) 2002-02-17
US5990102A (en) 1999-11-23
BR9510420A (pt) 2004-04-20
PL320937A1 (en) 1997-11-10
AU704407B2 (en) 1999-04-22
HUT77089A (hu) 1998-03-02
OA10737A (en) 2002-12-10

Similar Documents

Publication Publication Date Title
BG101687A (bg) Заместени азетидин-2-они за лечение на атеросклероза
ES2106965T3 (es) Nuevas 4-aza-5alfa-androstan-3-onas 7beta-sustituidas como inhibidores de 5alfa-reductasa.
ATE238790T1 (de) Verwendung von pramipexole als neuroschutzmittel
NO931795D0 (no) Dobbeltvirkende inhibitorer
NO970092L (no) Dihydrobenzofuraner
DE59611411D1 (de) Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz
BR9908280A (pt) Inibidores de enzimas de fosfolipase
ATE205365T1 (de) Enzymatische behandlung von kakao
LU88834A1 (de) Inhibitoren der Enzymaktivitaet von Rotamase
DK0841928T3 (da) Sustained release-formulering af d-threo-methylphenidat
ATE225772T1 (de) Thrombin-inhibitoren
DE69509236D1 (de) Entfernung von kontamination
FI914723A0 (fi) 17b-substituerade 4-aza-5a-androstan -3-jon-derivat och foerfarande foer framstaellning av desamma.
MX9800186A (es) Derivados de azetidinona para el tratamiento de ateroesclerosis.
DE69716367D1 (de) Herstellung von Siliziumsubstraten
PT871454E (pt) Inibidores fosforosos que contem protease de cisteina e de serina
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
DE69704189D1 (de) Verfahren zur Reinigung von Wasserstoffperoxid
DE69531048D1 (de) Verwendung von steroidsulphatase-hemmern
DE69720034D1 (de) PHENYLGLYOXAMIDE ALS sPLA2-INHIBITOREN
BG100248A (bg) Инхибитори на скваленсинтетаза
NO990450D0 (no) Behandling av sinnslidelser
NO952427D0 (no) Metode for behandling av kronisk prostatitt med 17 substituerte karbamoyl-4-aza-5
DE69917445D1 (de) Reinigung von carboxaldehyd
DE69807766D1 (de) Verfahren zur Behandlung von Silan-enthaltendem Gas